TheDinarian
News • Business • Investing & Finance
How Rockefeller Monopolized Medicine and Created BIG PHARMA
Please read and share, let the truth be known worldwide...
October 13, 2023
post photo preview

Born in 1839, John D. Rockefeller would go on to become one of the great robber barons and industrialist tycoons of American history. By the turn of the 20th century, Rockefeller controlled 90% of the oil refineries in the US through his company Standard Oil, becoming in the process America’s first billionaire.

Of course, in 1911, Standard Oil was ruled by the US Supreme Court to be an illegal monopoly in violation of antitrust laws and forced to break up. Like his father, John D. Rockefeller had built his success on illegality, cons, and scams.

Still, this was not enough for Rockefeller. He wanted more.

 

How Rockefeller Targeted Medicine

At the time, chemicals made from oil, known as ‘petrochemicals,’ were being discovered and developed in the US. This included the discovery that pharmaceutical drugs could be made from oil, which Rockefeller saw as an opportunity to expand his empire. The key was that petrochemicals, unlike natural health remedies, could be patented, presenting an enormous opportunity for Rockefeller profits.

There was only one problem – at the time, natural, herbal, and traditional medicines were very popular in the US. Something like half of the doctors and medical colleges in the country were using holistic medicine, natural remedies, and knowledge taken from Indigenous Native Americans. Rockefeller needed a way to eliminate the competition, to create a monopoly in medicine as he had done with oil.

And so, he went to his good friend Andrew Carnegie, another robber baron who had gotten rich through his monopoly of the steel industry and, incidentally, one of the country’s leading eugenicists. Together, the two men hatched a plan to take over American medicine.


maxresdefault.jpg

 

The Creation of Big Pharma

From the cover of the Carnegie Foundation, they would send a man named Abraham Flexner around the country to report on its medical colleges and hospitals. After visiting all 155 medical schools existing at that time in the US and Canada, he completed the seminal Flexner Report in 1910.

Following the directions of his employers, Flexner called in his report for a total restructuring of the American medical system, most specifically, for the pushing aside of natural and traditional remedies in favor of Rockefeller pharmaceuticals. The report even specifically mentioned the eradication of “dissidents,” appropriately, since this is exactly what happened.

Almost immediately after the report was issued, medical schools teaching things like naturopathy, homeopathy, electromagnetic field therapy, and so on, were told to drop these things or close. More than half of all medical colleges in the country did close, and many non-compliant doctors were demonized and even jailed.

But Rockefeller and Carnegie went further, offering huge grants to medical schools and hospitals so long as they only taught and practiced Rockefeller medicine, and allowed Rockefeller agents on their boards of directors to ensure compliance.

It was the carrot and the stick – those who agreed got funded with big money, those who didn’t were crushed.

In this way, all medical colleges in the country were streamlined and homogenized, with doctors all learning the same thing – how to use and prescribe Rockefeller’s patented drugs.

But, like any good monopolist, Rockefeller went further in seeking to consolidate his control. He took over the AMA and emboldened it as the gatekeeper of scientific thought and witch hunter of alternative medical practices. He took control of the FDA in order to control the approval process for new drugs. He even founded the American Cancer Society in 1913. Within a few short years, Rockefeller was in total control of the American medical system in both thought and action.

The result of this takeover, the product of this monopolist son of a conman and his eugenicist partner, would become known as “Big Pharma.”

That Big Pharma took over and monopolized American medicine, promoting their own patented, profit-making products and suppressing all others, isn’t even a conspiracy theory.

In fact, it was recorded for all to see in 1953 …

 

The Fitzgerald Report

In the early 1950s, US Senator Charles Toby enlisted an investigator with the Interstate Commerce Commission named Benedict Fitzgerald to examine allegations of conspiracy and monopoly in medicine. Toby had become interested in the issue after his own son had gotten cancer and been given less than two years to live by orthodox medicine before pursuing alternative treatments and being cured.

The resulting 1953 report, known as the Fitzgerald Report, was truly shocking. It concluded that Big Pharma had been involved in “a conspiracy of alarming proportions.”

First, there was

“The organized effort to hinder, suppress and restrict the free flow of drugs which allegedly proven successful in cases where clinical records, case history, pathological reports, and x-ray photographic proof, together with the alleged cured patients, are available.”

On top of that,

“Public and private funds have been thrown around like confetti at a country fair to close up and destroy clinics, hospitals, and research laboratories which do not conform to the viewpoint of medical associations.”

The report even noted that Big Pharma had conspired to suppress at least 12 promising cancer treatments, including mentioning Hoxsey Therapy by name.

It was an unfathomably damning report, making clear that the tentacles of a Big Pharma conspiracy to suppress alternative medicine were everywhere.

But as it turns out, the report did not go far enough

 

The Suppression of Laetril as a Cure for Cancer

Oftentimes when a new natural cancer treatment appears, the assertion from the medical establishment is that the new treatment is either unproven, or disproven. There is no better example of what this really means in the era of Big Pharma than the case of a cancer treatment called Laetrile.

In 1952, a year before the Fitzgerald Report, a biochemist named Ernst Krebs proposed that cancer was a deficiency disease which could be cured with a compound called amygdalin, found in over 1,200 plants, and most specifically in the seeds of apricots. By extracting this amygdalin from apricot kernels, Krebs created a product he called Laetrile.

Over the course of many years, Krebs conducted numerous lab experiments on animals which showed that Laetrile was an effective cancer treatment, that somehow, it caused cancer cells to self-destruct.

By the 1960s, a doctor named John Richardson had picked up the research, and had even begun treating human patients with Laetrile. Unsurprisingly, the Rockefeller-controlled FDA launched a massive media campaign against Richardson and Laetrile, claiming that the treatment was toxic and dangerous. By 1971, the FDA officially banned Laetrile, and, in 1972, they stormed Richardson’s clinic and arrested him.

But even after Richardson was jailed, people kept asking about Laetrile, writing to government officials, medical journals, and scientific labs demanding answers. At this point, Big Pharma knew they had to put their foot down once and for all. They needed to undertake official testing which proved that Laetrile didn’t work.

The testing would take place at Memorial Sloan-Kettering Cancer Center in New York City, and what would happen next would come to be described as “one of the biggest medical cover-ups the world of cancer research has ever seen.”

The tests would be led and directed by Dr. Kanematsu Sugiura, known at that time as “the preeminent cancer researcher in America.” He had over 60 years of experience, publishing hundreds of academic papers on the subject. As one scientist said, “When Dr. Sugiura publishes, we know we don’t have to repeat the study, for we would obtain the same results he has reported.”

In 1972, testing began, with Laetrile being administered to mice with many different types of cancerous tumors. At its completion, Dr. Sugiura concluded that Laetrile stopped the spread of cancer, inhibited the growth of tumors, and acted as a cancer prevention. It even provided relief from pain and improved general health.

This seemed to be incredible news. Except, there were three Rockefellers sitting on the board of Sloan-Kettering, as well as a dozen more people representing companies making big money from Big Pharma. When they caught word of the test results, “all hell broke loose,” and another round of tests was ordered.

Unfortunately for Sloan-Kettering executives, the second round of testing only confirmed the first. Except this time, with two confirmed tests from the legendary Dr. Sugiura in the books, mainstream media was forced to cover it. Had a cure for cancer really been found, they asked?

Sloan-Kettering officials refused to speak with the media, refused to discuss the results or answer any questions, saying only in a prewritten statement that a third round of tests had been ordered in order to “clarify” the results, as if they had not been twice clarified already.

In this third test, a new wrinkle would be introduced – Dr. Sugiura would be blinded. He would not know which half of the mice would be receiving Laetrile, and which half would be given a saline solution, as if this eminently respected scientist was going to somehow manipulate the results.

After four weeks, Dr. Sugiura could see which of the mice were being given Laetrile, since mice in some of the cages had fewer and smaller tumors, while mice in the other cages showed no effects. Sloan-Kettering overseers who were supervising the project confirmed to Dr. Sugiura that he was correct. For a third time, Laetrile’s cancer treating properties were confirmed.

Except, arguing that Dr. Sugiura was no longer blinded since he knew which cages were which, Sloan-Kettering officials shut the tests down.

They would try yet again to get the results they were looking for with a fourth test. This time, not only would Dr. Sugiura be blinded, but the mice who were receiving the treatment would be mixed together with those who weren’t. Dr. Sugiura warned that this was dangerous because there was no dependable way to ensure the lab techs administering the treatment would be able to identify the correct mice every time. And, in fact, this is exactly what happened. Some of the mice who were purportedly only being given a saline solution saw their tumors stop growing.

“There’s something funny here,” Dr. Sugiura professed. The ‘something funny’ was that the treatments had been mixed, with many mice receiving some Laetrile and some saline solution, just as Dr. Sugiura had predicted.

Yet, in this case, the legitimacy of the results wasn’t important to Sloan-Kettering’s Rockefeller board. Immediately, they announced that “results from the experiment do not confirm the earlier positive findings of Sugiura.”

Then, they called a press conference attended by most of mainstream media and declared, “Laetrile was found to possess neither preventive, nor tumor-regressant, nor anti metestatic, nor curative anti-cancer activity” – the exact opposite of what the first three tests had shown.

At the end of the press conference, the floor was opened to questions from the media, which is when things took a dramatic turn.

“Dr. Sugiura,” someone shouted, “Do you stick by your belief that Laetrile stops the spread of cancer?”

The room fell silent as the fabled Dr. Sugiura rose to his feet and replied, “I stick.”

The next month, Sloan-Kettering executives appeared before a Senate subcommittee hearing to decide the fate of Laetrile. While it had been banned by the FDA in 1971, some states were challenging this decision.

At the hearing, Sloan-Kettering executives asserted, “There is not a particle of scientific evidence to suggest that Laetrile possesses any anti-cancer properties at all” totally ignoring the three full lab tests of scientific evidence from “the preeminent cancer researcher in America.” As a result of the testimony, Laetrile was officially banned nationwide by 1980.

Afterwards, Dr. Sugiura was asked why Sloan-Kettering was so against Laetrile. “I don’t know,” he replied, “Maybe the medical profession doesn’t like it because they are making too much money.”

When Big Pharma says an alternative treatment has been disproven, this is what they mean.

 

Is Big Pharma Suppressing Information for Profit?

But what about if tests were not done in a Rockefeller-controlled lab. What if one were to do their own tests, build their own case studies, and present them to the appropriate authorities themselves?

One man provided an answer.

Stanislaw Burzynski was a Doctor of Biochemistry who immigrated to the US from Poland in 1970, where he took up a position as a researcher and assistant professor at Baylor University in Houston, Texas. There, he discovered something which he called antineoplastons – naturally occurring “molecular switches” in the human body which, Burzynski asserted, the body used to control cancer growth.

At first, Burzynski’s discoveries were well received by colleagues. In fact, so impressive was his work that he was offered a tenured position in Baylor’s Department of Pharmacology. He should have been thrilled, yet Burzynski knew that if he accepted, he would lose his independence as a researcher. So, he refused the position, instead choosing to found the Burzynski Research Institute in order to continue his work. On his way out the door at Baylor, his boss warned him, “Just wait, Burzynski. They’re going to kick your ass.”

In short order, Burzynski and his clinic were investigated by local medical authorities for using “unapproved medications,” while the Rockefeller-founded American Cancer Society put antineoplastons on its “unproven methods” list, and those who had been funding his research pulled their support.

In 1983, the FDA filed a lawsuit to get him to shut down his operation, and when this failed, FDA agents and federal marshals simply raided the Burzynski Research Institute and seized over 200,000 confidential documents.

Still Burzynski continued on. He raised millions of dollars through his Institute to pay for clinical trials for antineoplastons, money Big Pharma companies are more than happy to spend since they know they will recoup it when their products are patented. By the mid-90s, he was able to provide the FDA with sixty clinical trials, meeting the requirement for their Phase I testing.

For another decade he worked, compiling hundreds more clinical trials, meeting the requirements for Phase II of testing on his own at the cost of millions of dollars.

In 2011, Burzynski began Phase III testing, which involves thousands of participants and can last for years, again, at the cost of many millions of dollars. He was closing in on the finish line by 2013, which is when the FDA stepped in and put a stop to the trials. Their reason? They complained that the Burzynski Research Institute was doing all of the testing, when, of course, this is simply how the FDA approval process works. The only difference is usually the testing is being done by a Big Pharma company.

Finally, in 2017, the FDA cancelled antineoplaston clinical trials for good, refusing Burzynski the right to even conduct the tests. Moreover, Burzynski had his medical license revoked and was fined hundreds of thousands of dollars for his trouble.

The point made by Burzynski and his antineoplastons, by Sloan-Kettering’s Laetrile trials, is simple. It’s a case of ‘you’re damned if you do and damned if you don’t.’ If testing is conducted in a Rockefeller Big Pharma laboratory, it will be repeated and repeated and repeated until it gives the desired results, no matter how manipulated these results might be. And if you conduct the tests yourself, spending millions upon millions of dollars, the results will still not be accepted.

03-04-burzynski-02.webp?w=600&q=75&f=aa0b9051be2d61eaa37d43d89e96624f
Over 60 patients defended Dr. Burzynski stating they were cured by him.

Big Pharma controls the testing, they control approval, they control academic thought. But look closer, and it goes even further than that.

Big Pharma employs 1,270 registered lobbyists in the halls of government, more than two Big Pharma lobbyists for every member of congress, at a cost of over $200 million per year. They also spend tens of millions of dollars every year financing political campaigns – nearly every member of congress is funded by Big Pharma. On top of that, Big Pharma lobbyists and executives are repeatedly put in charge of the government bodies tasked with overseeing the pharmaceutical industry, like the FDA. Simply, the production and sale of medicine is tightly regulated by government, and Big Pharma controls the government.

Is it really so hard to believe that Big Pharma would use its control of academia, science, and government, to suppress valuable information for their own profit?

In reality, suppressing truth for profit is as American as apple pie – from the 1950s, when tobacco companies fought to suppress lung cancer knowledge as people died, to modern times, when oil companies insist that the debate around climate change is still ongoing, even as the consequences scientists promised decades ago are all around.

But pharmaceutical companies? Those purportedly tasked with providing health? Would they really suppress a cure for cancer? And kill people?

Actually, that Big Pharma would knowingly and intentionally kill people for profit is not conspiracy, it is established fact, admitted on record in American courts.

 

How Big Pharma Created the American Opioid Crisis

In October of 2020, Big Pharma flagbearer Purdue Pharma pled guilty in court to criminal charges for its role in the American opioid crisis, agreeing to pay some $8.3 billion in the settlement.

Opioids were a new type of synthetic pain medication that emerged in the early-1990s, which Big Pharma companies like Purdue aggressively promoted while suppressing information about the dangers, most specifically, the extreme addictiveness. Today, not only is chronic pain more prevalent than ever in the US, but nearly a million people have died from opioid overdoses, and another 3 million have fallen victim to addiction.

In pleading guilty at trial, Purdue Pharma admitted on record to having supplied drugs “without legitimate medical purpose.” In other words, the purpose of opioids wasn’t medical, it wasn’t to cure pain; it was to get people addicted so they’d buy more. Purdue even admitted to paying off health insurance companies to deny coverage for alternative care, forcing people to take opioids, and paying off doctors to overprescribe their product to patients.

depositphotos_178773006-stock-photo-macro-of-oxycodone-opioid-tablets.jpg

By February of 2022, four more of the largest Big Pharma companies had reached a $26 billion settlement for their own role in the crisis. These, along with Purdue, are the largest and most powerful pharmaceutical companies in the country, the ones who lobby governments and sit on medical boards. And here they are, on the record, poisoning people for profit.

 

Chemotherapy - The Only Legal "Cure" for Cancer

Apply this knowledge to cancer specifically, and think about what chemotherapy is.

The treatment was first conceptualized by doctors examining soldiers who had been exposed to mustard gas during World War II. Noticing that mustard gas had toxic effects on the blood cells of soldiers, doctors surmised that it could be used against cancer cells.

This was how the first version of chemotherapy, and model for all subsequent versions, was created, from a compound used as an agent of chemical warfare. This is what Big Pharma is telling cancer patients to put in their body.

Of course, it is no big secret that chemotherapy is toxic. Cancer patients are warned that side effects can include everything from vomiting and nausea, to infertility, to organ damage, and even death. They are even warned it can lead to a “second cancer.” In other words, patients are told chemotherapy might treat their cancer, but that it might also cause cancer; it might save their life, but it might also kill them. As one former president of the American Chemical Society succinctly put it, “chemotherapy does much, much more harm than good.”

A bit like opioids …

But that’s the point; there are no profits in the cure. Big Pharma needs people sick, so that people need more and more expensive “treatment.”

In this, the era of Big Pharma is alone in the history of medicine …

Link

The Dinarian On Locals is a labor of love that I pour my heart and soul into during my personal time. Countless hours are dedicated to delivering you the most up-to-date, unfiltered, and authentic news and information. Your support means the world to me, and I invite you to consider making a donation or becoming a dedicated supporter of this project. Any amount of XRP donations can be sent by scanning the QR code below and are greatly appreciated. ~ Namaste🙏🏼The Dinarian

 

 

community logo
Join the TheDinarian Community
To read more articles like this, sign up and join my community today
1
What else you may like…
Videos
Podcasts
Posts
Articles
🚀 Big XRPL-AXELAR News! 🌉

DeFi builders are innovating on XRP Ledger.

Interoperability enables seamless asset swaps and open finance across networks—fueling growth in decentralized applications and driving global adoption.

🚀 Big News! 🌉

We’ve officially integrated @squidrouter on XRiSE33 – powered by
@axelar! Now you can effortlessly bridge assets from 80+ chains directly into the XRPL EVM—no extra steps required. 🔁

🔥 Try it now at https://xrise33.com/bridge and experience zero friction DeFi!

00:00:44
BNY Mellon , @ripple Custody Partner, Q2 2025 Earnings Call😉
00:03:01
👀Dr. Robert Malone says RFK Jr. receive👽

Dr. Robert Malone says RFK Jr. received a classified briefing on UFOs, UAPs, and whether they could be interdimensional beings or time travelers.

Malone claims a federal investigator told him "alien encounters" are ramping up—and confirms they’re real.

OP: Shadowofezra

00:02:02
👉 Coinbase just launched an AI agent for Crypto Trading

Custom AI assistants that print money in your sleep? 🔜

The future of Crypto x AI is about to go crazy.

👉 Here’s what you need to know:

💠 'Based Agent' enables creation of custom AI agents
💠 Users set up personalized agents in < 3 minutes
💠 Equipped w/ crypto wallet and on-chain functions
💠 Capable of completing trades, swaps, and staking
💠 Integrates with Coinbase’s SDK, OpenAI, & Replit

👉 What this means for the future of Crypto:

1. Open Access: Democratized access to advanced trading
2. Automated Txns: Complex trades + streamlined on-chain activity
3. AI Dominance: Est ~80% of crypto 👉txns done by AI agents by 2025

🚨 I personally wouldn't bet against Brian Armstrong and Jesse Pollak.

👉 Coinbase just launched an AI agent for Crypto Trading
📈The Psychology Of A Market Cycle 📈

It's no where near over folks, I see hope.. 😉

post photo preview
👀Live Feed Of PYTH Tracking XRP/USD

Check it out live: 👇

https://insights.pyth.network/price-feeds/Crypto.XRP%2FUSD

👉 On the top right hit the "CTRL K" and start typing any ticker, pretty awesome, for a crypto geek like me anyway. 😉

post photo preview

Pyth is bringing the price of everything to the Global Market Alliance 🔮

Pyth Network is excited to join @OndoFinance's expanding network of financial infrastructure partners, including wallets, exchanges, and custodians, to accelerate the development of on-chain capital markets.

https://x.com/PythNetwork/status/1947690188702159076

post photo preview
Understanding the Crypto Alt Season

The next altcoin season is poised to ignite the crypto market, promising to turn savvy investors' portfolios into goldmines. As Bitcoin's dominance wanes, a new era of blockchain innovation is dawning—are you ready to ride the wave?

Market behavior often exhibits distinct patterns and cycles. One such phenomenon that has captured the attention of traders and investors alike is the "Alt Season"—a period when alternative cryptocurrencies, or "altcoins," outperform Bitcoin and experience significant price surges.

The concept of market cycles and seasonality is not unique to crypto; it's a well-established principle in traditional financial markets. However, in volatile crypto space, these cycles can be more pronounced and occur with greater frequency.  

In this article, we’ll try to cover these and other topics: 

  1. The nature and characteristics of Alt Seasons
  2. The importance of recognizing market cycles in cryptocurrency trading
  3. Alt Season indicators and how to interpret them
  4. Predictions and speculatins about the next potential Alt Season

What Is Crypto Alt Season?

Crypto Alt Season, short for "Alternative Cryptocurrency Season," refers to a period in the cryptocurrency market when alternative cryptocurrencies (altcoins) significantly outperform Bitcoin in terms of price appreciation. During an Alt Season:

  1. Many altcoins experience rapid price increases.
  2. The market share of altcoins grows relative to Bitcoin.
  3. Trading volume for altcoins typically increases.
  4. Investor attention shifts from Bitcoin to various altcoin projects.

An Alt Season can last anywhere from a few weeks to several months. It's often characterized by increased risk appetite among investors, who are willing to allocate more capital to smaller, potentially higher-risk crypto projects in search of higher returns.

Is Crypto Season the Same As Crypto Alt Season?

While related, Crypto Season and Crypto Alt Season are not exactly the same:

  1. Crypto Season:
    • Refers to a broader bullish period in the entire cryptocurrency market.
    • Typically includes price appreciation for both Bitcoin and altcoins.
    • Can be longer in duration, sometimes lasting for many months or even a year or more.
    • Often starts with a Bitcoin rally, followed by increased interest in the broader crypto market.
  2. Crypto Alt Season:
    • Specifically focuses on the outperformance of altcoins compared to Bitcoin.
    • Can occur within a broader Crypto Season but is more narrowly defined.
    • Generally shorter in duration than a full Crypto Season.
    • May happen towards the latter part of a broader Crypto Season, as investors seek higher returns in smaller cap coins.

Key Differences:

  • Scope: Crypto Season encompasses the entire market, while Alt Season focuses on altcoins.
  • Duration: Crypto Seasons are generally longer than Alt Seasons.
  • Market Dynamics: In a Crypto Season, Bitcoin often leads the rally, while in an Alt Season, altcoins outperform Bitcoin.

It's important to note that these terms are not officially defined and can be subject to different interpretations within the cryptocurrency community. However, understanding the distinction can help investors and traders better analyze market trends and potential opportunities in different segments of the crypto market.

What Is Alt Season Indicator?

The Alt Season Indicator is a tool used by cryptocurrency traders and investors to gauge whether the market is entering or currently in an "Alt Season" — a period when altcoins are outperforming Bitcoin. While there isn't a single, universally accepted Alt Season Indicator, several metrics and tools are commonly used to assess the likelihood of an Alt Season. Here are some key aspects of Alt Season Indicators:

Bitcoin Dominance

One of the most widely used indicators is Bitcoin Dominance, which measures Bitcoin's market capitalization as a percentage of the total cryptocurrency market cap.

  • Calculation: (Bitcoin Market Cap / Total Crypto Market Cap) * 100
  • Interpretation: A declining Bitcoin Dominance often signals a potential Alt Season, as it indicates that capital is flowing from Bitcoin into altcoins.
  • Threshold: Some traders consider Bitcoin Dominance below 50% as a potential indicator of an Alt Season.

Altcoin Market Cap Ratio

This indicator compares the total market capitalization of altcoins to Bitcoin's market cap.

  • Calculation: Total Altcoin Market Cap / Bitcoin Market Cap
  • Interpretation: An increasing ratio suggests growing strength in the altcoin market relative to Bitcoin.

Top 10 Altcoins Performance

This indicator tracks the performance of the top 10 altcoins by market cap (excluding Bitcoin) compared to Bitcoin over a specific period.

  • Calculation: Average percentage gain of top 10 altcoins vs. Bitcoin's percentage gain
  • Interpretation: When a majority of top altcoins consistently outperform Bitcoin, it may indicate an Alt Season.

Alt Season Index

Some crypto data platforms offer a proprietary Alt Season Index, which combines various metrics to provide a single score indicating the likelihood of an Alt Season.

  • Scale: Often presented as a percentage or a 0-100 score
  • Interpretation: Higher scores (e.g., above 75%) suggest a higher probability of an ongoing Alt Season

Trading Volume Ratios

This indicator compares the trading volumes of altcoins to Bitcoin's trading volume.

  • Calculation: Total Altcoin Trading Volume / Bitcoin Trading Volume
  • Interpretation: An increase in this ratio may indicate growing interest in altcoins, potentially signaling an Alt Season.

Important Considerations:

  1. No single indicator is foolproof. Traders often use a combination of indicators for a more comprehensive analysis.
  2. Market conditions can change rapidly, and past patterns don't guarantee future results.
  3. Different traders may use different thresholds or interpretations of these indicators.
  4. The crypto market's evolving nature means that indicators may need to be adjusted over time to remain relevant.

Understanding and effectively using Alt Season Indicators can help traders and investors make more informed decisions about allocating their resources between Bitcoin and altcoins. However, it's crucial to combine these indicators with broader market analysis and risk management strategies.

Alt Seasons: Historical Perspective, Current Situation, and Future Predictions

Previous Altcoin Seasons

In crypto, two periods stand out as particularly significant for altcoins. These "alt seasons" saw unprecedented growth and interest in cryptocurrencies beyond Bitcoin, reshaping the landscape of digital assets.

The 2017-2018 Alt Season

Duration: December 2017 to January 2018

Context:

  • Bitcoin (BTC) experienced its most remarkable bull run to date, reaching nearly $20,000 in December 2017.
  • This surge in Bitcoin's price and public interest created a ripple effect throughout the crypto market.

Key Developments:

  1. Proliferation of New Coins: The success of Bitcoin catalyzed the launch of numerous new cryptocurrencies.
  2. Investor Frenzy: Buoyed by Bitcoin's success, investors eagerly sought the "next Bitcoin," pouring capital into various altcoins.
  3. ICO Boom: This period saw a surge in Initial Coin Offerings (ICOs), with many projects raising millions in a matter of hours or days.
  4. Market Expansion: The total cryptocurrency market cap reached unprecedented levels, briefly surpassing $800 billion in January 2018.

Notable Altcoins: Ethereum (ETH), Ripple (XRP), and Litecoin (LTC) saw significant price increases during this period.

The 2020-2021 Alt Season

Duration: December 2020 to April 2021

Context:

  • Bitcoin broke its previous all-time high, surpassing $60,000 in March 2021.
  • The COVID-19 pandemic had accelerated digital adoption and increased interest in alternative investments.

Key Developments:

  1. DeFi Explosion: Decentralized Finance (DeFi) projects gained massive traction, with many tokens seeing exponential growth.
  2. NFT Boom: Non-Fungible Tokens (NFTs) entered the mainstream, driving interest in blockchain-based digital assets.
  3. Institutional Adoption: Major companies and institutional investors began adding cryptocurrencies to their balance sheets.
  4. Technological Advancements: Many altcoins introduced innovative features, scaling solutions, and use cases.

Notable Altcoins: Ethereum (ETH) reached new highs, while projects like Binance Coin (BNB), Cardano (ADA), and Polkadot (DOT) saw remarkable growth.

Comparative Analysis: Both alt seasons shared some common characteristics:

  • They were preceded by significant Bitcoin price rallies.
  • New projects and tokens gained rapid popularity and valuation.
  • Retail investor participation increased dramatically.
  • The overall cryptocurrency market capitalization reached new heights.

However, the 2020-2021 alt season was marked by greater institutional involvement and a broader range of technological innovations, particularly in DeFi and NFTs.

Is It Alt Season?

Based on the indicators discussed above, it's not currently an altcoin season. The Altcoin Season Index at 41 and Bitcoin's market dominance at 61.3% both suggest that Bitcoin is still the dominant force in the crypto market at this time.

When Is Alt Season?

Based on the information we could gather from various experts, we can analyze the predictions for the next altcoin season as follows:

  • Based on the latest analysis from experts and on-chain data, here’s what we know about the next altcoin season:

     

    Current Status (August 2025):

     

    • The altcoin season index—a metric that signals how many altcoins outperform Bitcoin—currently sits around 37. For a “full-blown” alt season, it typically needs to rise above 75.

    • Bitcoin dominance is approximately 61-62%. Historically, dropping below 60% often coincides with a rapid rotation into altcoins and the start of alt season.

     

    Key Indicators to Watch:

     

    • Altcoin Season Index (ASI): Above 75 signals a true altcoin season.

    • Bitcoin Dominance: A move below 60% usually marks the transition; sub-50% dominance is associated with peak alt season inflows.

    • Market Activity: Increasing volumes in major altcoins and Layer 1s, meme coin rallies, and spikes in DeFi activity are early warning signs.

    • Ethereum Outperformance: When ETH surges relative to BTC, this historically precedes broader altcoin rallies.

     

    Expert Predictions for 2025:

     

    • Analysts point to a pivotal window for alt season starting as early as August 2025 and extending through the fall, with many expecting true acceleration of altcoin gains if Bitcoin’s price consolidates and capital rotates further into alts.

    • There is strong consensus that macroeconomic catalysts, such as potential U.S. interest rate cuts and ongoing Bitcoin ETF momentum, could fuel a major altcoin rally in late 2025 if positive conditions persist.

    Summary Table: Key Factors & Targets

    SignalAlt Season TriggerStatus (Aug 2025)
    Altcoin Season Index (ASI)>75 ~37
    Bitcoin dominance<60% ~61–62% (near trigger)
    Altcoin trading volumeSustained surge across many alts Rising, but not explosive
    Ethereum outperformanceETH/ BTC breakout, >$3,700 Near, ETH ~$3,500
    Market narrativesAI, DeFi, meme coins, new L1 inflows Strengthening
     

    Bottom Line:
    Most analysts agree the groundwork for altcoin season in 2025 is building. We are currently in a transition phase: if Bitcoin dominance continues to fall and the Altcoin Season Index rises above 75, a full-fledged alt season could ignite during the second half of 2025. Monitor these key indicators to stay ahead as market momentum shifts from Bitcoin into a broader range of altltcoins.

Key Factors to Consider

  • Technology: Look for coins with innovative solutions to existing blockchain challenges.
  • Adoption: Consider projects with growing partnerships and real-world use cases.
  • Market Position: Established coins with room for growth may offer a balance of stability and potential returns.
  • Tokenomics: Understanding supply dynamics can help predict potential price movements.

It's crucial to conduct thorough research before investing. The cryptocurrency market is highly volatile, and past performance doesn't guarantee future results. Always invest responsibly and within your risk tolerance.

How to Win in Next Alt Season?

Capitalizing on the next altcoin season requires a strategic approach. Here's how to maximize potential gains:

  • Research and Diversification: Thoroughly research potential investments, analyzing both fundamentals and technical aspects to identify promising altcoins. Diversify your holdings across different projects to mitigate risk and maximize potential returns. Don't put all your eggs in one basket.
  • Strategic Timing: Utilize technical analysis tools like support/resistance levels and RSI to pinpoint optimal entry and exit points. Monitor market sentiment and price trends to make informed decisions. A clear entry and exit strategy is crucial for managing risk and maximizing profits during volatile periods.
  • Newer Projects: Consider participating in newer altcoin projects. This provides early access to potentially high-growth projects at discounted prices. Research upcoming defi projects with use cases, focusing on innovative projects with strong potential. Investing early can yield substantial returns as the project develops.

Conclusion

In summary, an altcoin season, marked by significant price increases in non-Bitcoin cryptocurrencies, may be on the horizon.  This potential surge could be driven by investors seeking higher returns in smaller-cap cryptocurrencies, technological advancements in altcoin projects, increased blockchain adoption, and the transition of projects from speculative ventures to real-world applications

Remember, while the potential for significant gains exists during an altcoin season, the cryptocurrency market remains highly volatile. Always invest responsibly.

Source

🙏 Donations Accepted 🙏

If you find value in my content, consider showing your support via:

💳 PayPal: 
1) Simply scan the QR code below 📲
2) or visit https://www.paypal.me/thedinarian

🔗 Crypto – Support via Coinbase Wallet to: [email protected]

Read full Article
post photo preview
PYTH: We'll Always Have Coldplay

Welcome back to The Epicenter, where crypto chaos meets corporate cringe.

But surprisingly, crypto has not been the most chaotic corner of the internet as of late.

That honor goes to the startup Astronomer, whose CEO’s cheating scandal broke the web in a glorious meme-fueled media frenzy. The company’s damage control? Hiring Gwyneth Paltrow as a “temporary spokesperson.” Do we think they’re grasping at straws or setting a new standard for PR?

Meanwhile, the markets didn’t blink. BTC is still flexing near its all-time highs. Michael Saylor’s bringing a bitcoin-adjacent money-market product to Wall Street. A pharma company just earmarked $700M to stack BNB, and analysts are calling time of death on the four-year crypto cycle. It’s a steady boom now, kittens.

A few things that are also worth noting: Winklevoss vs. JPMorgan, Visa’s take on stablecoins, and Robinhood’s Euro drama that defies the chillness of eurosummer.

Let’s get into it 👇

⛓️ The On-Chain Pulse: What’s Happening on the Front Lines of Finance

This week’s biggest news in crypto and all things digital assets

🗣️ Word on the Street: What the Experts are Saying

Stuff you should repost (or maybe even cough reword and take credit for)

Meme of the Week

🏦 Kiss my SaaS: What’s Changing the Game for Fintech

Things you should care about if you want to impress your coworkers

Closing Thoughts

From meme-fueled PR stunts to Bitcoin-backed money-market funds, this week reminded us that markets move fast—and headlines move faster. With Wall Street automating itself, fintechs beefing with banks, and even your smartphone becoming a miner, anything is possible. Stay curious, stay cynical, and as always—stay sharp and stay liquid. We’ll see you back here in two weeks.

— The Epicenter, powered by Pyth Network

 

🙏 Donations Accepted 🙏

If you find value in my content, consider showing your support via:

💳 PayPal: 
1) Simply scan the QR code below 📲
2) or visit https://www.paypal.me/thedinarian

🔗 Crypto – Support via Coinbase Wallet to: [email protected]

 

Read full Article
post photo preview
4 Fintech Companies 💸& Things To Know About 🤔

The fintech revolution is reshaping the way we manage, invest, and move money, breaking down traditional barriers and empowering individuals worldwide. As financial technology continues to evolve at a rapid pace, a select group of innovative companies are leading the charge by offering groundbreaking solutions that redefine banking, payments, and digital assets. Whether you’re a savvy investor, an industry professional, or simply curious about the future of finance, discovering these trailblazing fintech companies is essential to understanding today’s dynamic financial landscape.

 

  1.  Alina Invest - The AI Wealth Manager for GenZ Women

Alina is aimed at women under 25 who identify as beginner investors. They're an SEC-registered investment advisor that charges $120/year for membership. The service "buys and sells for you" and gives up notification updates of recent transactions like a wealth manager would.

👉 Getting people to invest early is crucial to building long-term wealth. One thing that holds them back is a lack of confidence and experience. Being targetted "for beginners" and people who live on TikTok should appeal. I love the sense of "we're buying and selling for you." Funds always do that, but making it an engagement mechanic is very smart. The risk here is that building a wealth business will take decades for the AUM to compound. But the next generations, Wealthfront or Betterment, will look something like Alina.

2. Blue layer - The Carbon project funding platform

Bluelayer allows Carbon project developers to take from feasibility studies to issuing credits, tracking inventory, and managing orders. Developers of reforestation, conservation, direct air capture, and other projects can also directly report to industry registries. 

👉 Carbon investing and tax credits are heavily incentivized but need transparent data. By focusing on the developers, Bluelayer can ensure the data, reporting, and credits lifecycle is all managed at the source. This is smart.

3. Akirolabs - Modern Procurement for enterprise

Akiro is a "strategic" procurement platform aiming to help enterprise customers identify risks, value drivers, and strategic levers before issuing an RFP. It aims to bring in multiple stakeholders for complex purchasing decisions at multinationals. 

👉 Procurement is a great wedge for multinational corporate transformation. Buying anything in an enterprise that uses large-scale ERPs is a nightmare of committees and spreadsheets. Turning an oil tanker-sized organization around is difficult, but the right suppliers can have a meaningful impact in the short term. That only works if you can buy from them. Getting people on the same page with a single platform is a great start.

4. NeoTax - Automated Tax R&D Credits

NeoTax allows companies to connect their engineering tools to calculate available tax advantages automatically. Once calculated, the tax fillings are clearly labeled with supporting evidence for the IRS.

👉 AWS and GCP log files and data are a goldmine. Last week, I covered Bilanc, which uses log files to figure out per-account unit economics. Now, we calculate R&D tax credits. The unlock here is LLM's ability to understand unstructured data. The hard part is understanding the moat, but time will tell.

In an era where technology and finance are increasingly intertwined, these four fintech companies stand out as catalysts for positive change. By driving progress in digital payments, asset management, lending, and decentralized finance, they are not only making financial services more accessible and efficient—they are also paving the way for a more inclusive and empowered global economy. Staying informed about their innovations can help you seize new opportunities and take part in the future of finance.

 

👀Things to know 👀

 

PayPal issued low guidance and warned of a “transition year.” The stock is down 8% in extended trading despite PayPal reporting a 9% growth in revenue and 23% EBITDA. Gross profit is down 4% YoY. PayPal's total revenues were $29Bn for the year

Adyen reported 22% revenue growth and an EBITDA margin of 46% for the full year. Adyen's total revenues were $1.75bn for the full year. The margin was down from 55% the previous year, impacted by hiring ahead of growth.

🤔 PayPal’s Braintree (unbranded) is losing market share in the US, while Adyen is winning it. eCommerce is growing ~9 to 10% YoY, and PayPal’s transaction revenue grew by 6.7%. The higher interest rate environment meant interest on balances dragged up the total revenue figure. Their core business is losing market share. Adyen is outgrowing the market by ~12%.

🤔 The PayPal button (branded) is losing to SHOP Pay and Apple Pay. The branded experience from Apple and Shopify is delightful for users; it’s fast and helps with small details like delivery tracking. That experience translates to higher conversion (and more revenue) for merchants.

🤔 The lack of a single global platform hurts PayPal, but it helps Adyen. In the earnings call, the new CEO admitted their mix of platforms like Venmo, PayPal, and Braintree are holding them back. They aim to combine and simplify, but that’s easier said than done.

🤔 Making a single platform from PayPal, Venmo, and Braintree won’t be easy. There’s a graveyard of payment company CEOs who tried to make “one platform” from things they acquired years ago. It’s crucial if they’re going to grow that they get their innovation edge back. Adyen has one platform in every market.

🤔 PayPal’s UK and European acquiring business is a bright spot. The UK and EU delivered 20% of overall revenue, growing 11% YoY. Square and Toast don’t have market share here, while iZettle, which PayPal acquired in 2018, is a strong market player. Overall though, it’s yet another tech stack and business that’s not part of a single global platform.

The two banks provided accounts to UK front companies secretly owned by an Iranian petrochemicals company. PCC has used these entities to receive funds from Iranian entities in China, concealed with trustee agreements and nominee directors. 

🤔 This is the headline every bank CEO fears. Oof. Shares of both banks have been down since the news broke, but this will no doubt involve crisis calls, committees, appearing in front of the regulator, and, finally, some sort of fine.

🤔 The "risk-based approach" has been arbitraged. A UK company with relatively low annual revenue would look "low risk" at onboarding. One business the FT covered looked like a small company at a residential address to compliance staff. They'd likely apply branch-level controls instead of the enterprise-grade controls you'd see for a large corporation. 

🤔 Hiring more staff won't fix this problem; it's a mindset and technology challenge. In theory, all of the skill and technology that exists to manage risks with large corporate customers (in the transaction banking divisions) are available to the other parts of a bank. In practice, they're not. Most banks lack a single data set and the ability for compliance officers in one team to see data from another part of the org. Getting the basics right with data and tooling is incredibly hard and will involve a multi-year effort. 

🤔 These things are rarely the failure of an individual or department; the issue is systemic. While two banks are named in this headline, the issue is everywhere. Banks need more data and better data to train better AI and machine learning. That all needs to happen in real-time as a compliment to the human staff. Throwing bodies at this won't solve the visibility issue teams have.

 🙏 Donations Accepted 🙏

If you find value in my content, consider showing your support via:

💳 PayPal: 

1) Simply scan the QR code below 📲
2) or visit https://www.paypal.me/thedinarian

🔗 Crypto – Support via Coinbase Wallet to: [email protected]

Or Buy me a coffee: https://buymeacoffee.com/thedinarian

Your generosity keeps this mission alive, for all! Namasté 🙏 Crypto Michael ⚡  The Dinarian

 

Read full Article
See More
Available on mobile and TV devices
google store google store app store app store
google store google store app tv store app tv store amazon store amazon store roku store roku store
Powered by Locals